Back to Search
Start Over
Evaluation of transmission-blocking potential of PvPSOP25 using transgenic murine malaria parasite and clinical isolates.
- Source :
-
PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2024 Jun 12; Vol. 18 (6), pp. e0012231. Date of Electronic Publication: 2024 Jun 12 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- Background: Malaria transmission-blocking vaccines (TBVs) aim to inhibit malaria parasite development in mosquitoes and prevent further transmission to the human host. The putative-secreted ookinete protein 25 (PSOP25), highly conserved in Plasmodium spp., is a promising TBV target. Here, we investigated PvPSOP25 from P. vivax as a TBV candidate using transgenic murine parasite P. berghei and clinical P. vivax isolates.<br />Methods and Findings: A transgenic P. berghei line expressing PvPSOP25 (TrPvPSOP25Pb) was generated. Full-length PvPSOP25 was expressed in the yeast Pichia pastoris and used to immunize mice to obtain anti-rPvPSOP25 sera. The transmission-blocking activity of the anti-rPvPSOP25 sera was evaluated through in vitro assays and mosquito-feeding experiments. The antisera generated by immunization with rPvPSOP25 specifically recognized the native PvPSOP25 antigen expressed in TrPvPSOP25Pb ookinetes. In vitro assays showed that the immune sera significantly inhibited exflagellation and ookinete formation of the TrPvPSOP25Pb parasite. Mosquitoes feeding on mice infected with the transgenic parasite and passively transferred with the anti-rPvPSOP25 sera showed a 70.7% reduction in oocyst density compared to the control group. In a direct membrane feeding assay conducted with five clinical P. vivax isolates, the mouse anti-rPvPSOP25 antibodies significantly reduced the oocyst density while showing a negligible influence on mosquito infection prevalence.<br />Conclusions: This study supported the feasibility of transgenic murine malaria parasites expressing P. vivax antigens as a useful tool for evaluating P. vivax TBV candidates. Meanwhile, the moderate transmission-reducing activity of the generated anti-rPvPSOP25 sera necessitates further research to optimize its efficacy.<br />Competing Interests: The authors have declared that no competing interests exist.<br /> (Copyright: © 2024 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Subjects :
- Animals
Mice
Humans
Female
Antigens, Protozoan genetics
Antigens, Protozoan immunology
Antibodies, Protozoan blood
Antibodies, Protozoan immunology
Malaria transmission
Malaria prevention & control
Malaria parasitology
Malaria immunology
Mice, Inbred BALB C
Plasmodium vivax genetics
Plasmodium vivax immunology
Malaria Vaccines immunology
Malaria Vaccines administration & dosage
Plasmodium berghei genetics
Plasmodium berghei immunology
Protozoan Proteins genetics
Protozoan Proteins immunology
Malaria, Vivax transmission
Malaria, Vivax parasitology
Malaria, Vivax prevention & control
Malaria, Vivax immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1935-2735
- Volume :
- 18
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- PLoS neglected tropical diseases
- Publication Type :
- Academic Journal
- Accession number :
- 38865344
- Full Text :
- https://doi.org/10.1371/journal.pntd.0012231